Publication Name	World Journal of Clinical Cases
Manuscript ID	14334
Country

Received	2014-09-29 08:39
Peer-Review Started	2014-09-29 21:11
To Make the First Decision	2014-12-17 11:24
Return for Revision	2014-12-19 13:42
Revised	2014-12-30 00:25
Second Decision	2015-06-12 08:21
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-06-19 17:17
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-08-08 16:23
Publish the Manuscript Online	2015-08-21 13:58

ISSN	2307-8960 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Urology & Nephrology
Manuscript Type	Case Report
Article Title	Rituximab therapy for primary glomerulonephritis: Report on two cases
Manuscript Source	Unsolicited Manuscript
All Author List	Fabrizio Fabrizi, Donata Cresseri, Giovanni B Fogazzi, Gabriella Moroni, Patrizia Passerini, Paul Martin and Piergiorgio Messa
Funding Agency and Grant Number
Corresponding Author	Fabrizio Fabrizi, MD, Division of Nephrology, Maggiore Hospital, IRCCS Foundation, Pad. Croff, via Commenda 15, 20122 Milano, Italy. fabrizi@policlinico.mi.it
Key Words	Chronic kidney disease; Cryoglobulinemic vasculitis; Membranoproliferative glomerulonephritis; Rituximab
Core Tip	A small but growing body of evidence is emerging on the efficacy and safety of rituximab therapy for primary glomerulonephritis. Various authors have claimed that rituximab for glomerular diseases is effective and has minimal adverse effects. We report on two male Caucasian patients who were refractory to conventional immunosuppressive therapy; each of them received one rituximab pulse and developed sepsis over the follow-up, the first patient died two months after rituximab therapy. The risks (and the predictive factors) of severe infections in kidney patients on rituximab therapy are unclear and appear an area of active research.
Publish Date	2015-08-21 13:58
Citation	Fabrizi F, Cresseri D, Fogazzi GB, Moroni G, Passerini P, Martin P, Messa P. Rituximab therapy for primary glomerulonephritis: Report on two cases. World J Clin Cases 2015; 3(8): 736-742
URL	http://www.wjgnet.com/2307-8960/full/v3/i8/736.htm
DOI	http://dx.doi.org/10.12998/wjcc.v3.i8.736

Full Article (PDF)	WJCC-3-736.pdf
Full Article (Word)	WJCC-3-736.doc
Manuscript File	14334-Review.doc
Answering Reviewers	14334-Answering reviewers.pdf
Audio Core Tip	14334-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	14334-Conflict-of-interest statement.pdf
Copyright License Agreement	14334-Copyright assignment.pdf
Institutional Review Board Approval Form or Document	14334-Institutional review board statement.pdf
Peer-review Report	14334-Peer-review(s).pdf
Scientific Misconduct Check	14334-Scientific misconduct check.pdf
Scientific Editor Work List	14334-Scientific editor work list.pdf